The pre‐ and post‐authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation. Issue 3 (23rd January 2020)

• Record Type: Journal Article
• Authors: Ghalandari, N.; Dolhain, R.J.E.M.; Hazes, J.M.W.; Siezen, C.L.E.; van der Laan, J.W.; Crijns, H.J.M.J.; van Puijenbroek, E.P.; van der Woude, C.J.
• Is Part Of: British journal of clinical pharmacology. Volume 86:Issue 3(2020)
• Page Start: 580
• Page End: 590
• Publication Date: 2020-01-23
• Subjects: biologics -- gastroenterology -- lactation -- pregnancy -- rheumatology; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.14145
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Aims: The effects of biologics on reproduction/lactation are mostly unknown although many patients that receive biologics are women of reproductive age. The first objective of this study was to investigate the publicly available data on pregnancy/lactation before and after marketing authorization in Europe of biologics for the indications of rheumatologic inflammatory autoimmune diseases and inflammatory bowel disease. Secondary objectives included the assessment of the clinical relevance of the provided data and comparison of initial and post‐authorization data. Methods: Initial and post‐authorization data were extracted from the European Public Assessment Reports and the latest versions of Summary of Product Characteristics using publicly available documents on the European Medicines Agency's website. Four sections were categorized regarding pregnancy outcomes: pre‐clinical/animal studies, human female fertility, pregnancy‐related outcomes and congenital malformations in the human fetus. Three sections were categorized regarding lactation outcomes: pre‐clinical/animal studies, excretion in human breast milk and absorption in children through breastfeeding. The clinical applicability of each category was scored by specified criteria, based on scientific literature, and further as defined by the authors. Results: For the 16 included biologics, post‐authorization data were delivered only for adalimumab, certolizumab pegol, etanercept and infliximab. For the 12 remaining biologics limited data on pregnancy and lactation during the post‐marketing period of 2–21 years were available. Conclusions: In this article several suggestions are provided for improving a multidisciplinary approach to these issues. The initiation of suitable registries by marketing authorization holders and data transparency for clinicians and academics are highly endorsed.